Product
cediranib
Aliases
RECENTIN
2 clinical trials
1 drug
2 abstracts
3 indications
Indication
Solid TumorsDrug
cediranibIndication
Alveolar Soft Part SarcomaIndication
NSCLCClinical trial
An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).Status: Active (not recruiting), Estimated PCD: 2024-09-04
Clinical trial
A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTIN™), in Patients With Advanced Solid TumoursStatus: Active (not recruiting), Estimated PCD: 2009-07-30